Despite significant advances in diabetes care, insulin initiation and persistence remain challenging due to treatment complexity, injection burden, and adherence issues. Once-weekly basal insulin has emerged as an innovative approach that has the potential to simplify insulin therapy while maintaining effective glycaemic control. Awiqli® (insulin icodec) is the first once-weekly basal insulin designed to provide stable glucose-lowering efficacy with a reduced injection frequency, potentially improving treatment acceptance and long-term adherence in appropriate patients.¹⁻³ Agenda The introduction of once-weekly basal insulin represents an important advancement in diabetes management, offering an opportunity to address barriers associated with daily insulin therapy while delivering sustained glycaemic control.
Join Dr. Subhash Wangnoo as he discusses the clinical evidence supporting…
